Brief: Kronos Bio Announces FDA Clearance Of IND Application For Lanraplenib

Kronos Bio

27/07/2021 14:02

July 27 (Reuters) - Kronos Bio Inc  KRON.O :
    * KRONOS BIO ANNOUNCES FDA CLEARANCE OF INVESTIGATIONAL NEW
DRUG
APPLICATION FOR LANRAPLENIB (LANRA) FOR TREATMENT OF PATIENTS
WITH ACUTE MYELOID LEUKEMIA (AML)
    * KRONOS BIO INC - TWO PHASE 1/2 CLINICAL TRIALS OF LANRA
ARE
PLANNED, WITH FIRST TRIAL TO INITIATE IN Q4 2021
    * KRONOS BIO INC - INTENDS TO DEVELOP LANRA AS A ONCE-DAILY
CHRONIC TREATMENT FOR GENETICALLY-DEFINED AML PATIENTS
    * KRONOS BIO - INITIAL DATA FROM FIRST STAGE OF FIRST OF TWO
PLANNED PHASE 1/2 CLINICAL TRIALS ARE ANTICIPATED TO BE
AVAILABLE IN SECOND HALF OF 2022
    * KRONOS BIO INC - IN FIRST HALF OF 2022, CO PLANS TO
INITIATE A
SECOND PHASE 1/2 CLINICAL TRIAL OF LANRA
    * KRONOS BIO INC - ANTICIPATES INITIAL DATA FROM SECOND
PHASE 1/2
CLINICAL TRIAL OF LANRA IN FIRST HALF OF 2023

Source text for Eikon:  ID:nGNX6g3DtT 
Further company coverage:  KRON.O 

 ((Reuters.Briefs@thomsonreuters.com;))